This rise was due to alterations at a low percentage in genes with proven predictive value in the context of approved anti-cancer drugs (e.g., EGFR, BRAF, ERBB2, BRCA1, BRCA2, RET, ALK) in all cancer types (Additional file 3). This evidence concerns the gene ALK and cancer.